Breaking Europe Battles Widespread Wildfires Amidst Heatwave and Drought UEFA Expresses Loss of Confidence in FIFA President Infantino Over Withdrawn World Cup Investment Plan Michigan Democratic Senate Primary Pits Establishment Against Progressive Wing U.S. President Threatens Further Strikes on Iran Amid Regional Tensions Wall Street Braces for Week of Key Corporate Earnings and Economic Data

Saturday August 1, 2026

Reporter

Dyne Therapeutics, Inc.

5Articles Published

5Communities Covered

Published Articles

Press Release

Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Jul 29

Press Release

Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)

Jul 28

Press Release

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 24

Press Release

Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Jul 23

Press Release

Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock

Jul 21